Date Title Description PDF
29 Sep 2025 On corporate transactions: mergers, acquisitions and others ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) Download
29 Sep 2025 On corporate transactions: mergers, acquisitions and others The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) Download
24 Jul 2025 On P&L The Company releases the press release related to the first half of 2025 financial results Download
24 Jul 2025 On P&L The Company releases the first half 2025 financial results presentation Download
25 Mar 2025 On business and financial situation The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day Download

Pages

Date Title Description PDF
28 Jul 2023 On business and financial situation ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® Download
05 Jul 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2023 Download
26 Jun 2023 Other relevant information The Company informs about the dividends payment Download
14 Jun 2023 Announcement of general shareholders’ meeting ROVI releases the information related to its General Shareholders Meeting. Download
31 May 2023 Other relevant information ROVI informs about the news items that have appeared in several media today regarding ROVI’s receipt of government grants Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages